Equities

Zhaoke Ophthalmology Ltd

Zhaoke Ophthalmology Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.57
  • Today's Change0.00 / 0.00%
  • Shares traded1.34m
  • 1 Year change-57.91%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024 08:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhaoke Ophthalmology Ltd is a China-based investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs. The Company’s products include innovative drugs and generic drugs. The Company ‘s products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.

  • Revenue in HKD (TTM)20.26m
  • Net income in HKD-416.06m
  • Incorporated2020
  • Employees313.00
  • Location
    Zhaoke Ophthalmology LtdNo. 1 Meide 3rd Road, Pearl RiverIndustrial Park, Nansha DistrictGUANGZHOU ChinaCHN
  • Phone+86 2 039062888
  • Websitehttps://www.zkoph.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sirnaomics Ltd0.00-615.64m602.87m145.00--1.92-----8.10-8.100.003.590.00----0.00-70.91---71.22--------------0.6176------10.88------
Genor Biopharma Holdings Ltd0.00-728.70m639.84m104.00--0.4932-----1.44-1.440.002.530.000.00--0.00-37.91-55.46-44.02-63.73--66.56---14,819.185.38--0.006---100.00--7.65------
Pak Fah Yeow International Ltd259.16m105.04m651.33m102.006.200.85125.792.510.3370.3370.83162.460.29952.8822.182,540,765.0012.143.9912.604.1884.4580.7940.5321.276.9010.080.0062100.6876.0612.94250.6623.0218.83-8.06
Lee's Pharmaceutical Holdings Ltd1.05bn16.70m653.61m1.06k39.140.32063.860.62070.02840.02841.793.460.37131.8310.75996,247.900.703313.330.8817.7652.3561.921.8936.200.55263.900.09433.59-14.61-1.53-67.44-47.49-12.19-31.34
Fusen Pharmaceutical Co Ltd611.18m-39.20m666.60m1.15k--1.0918.531.09-0.0525-0.05250.81270.81230.41991.954.47532,390.40-2.690.9678-5.541.7452.9551.95-6.422.590.60960.710.3797--15.024.13-4.83------
Antengene Corporation Ltd72.73m-628.01m687.50m201.00--0.5545--9.45-1.02-1.020.11821.840.03580.97733.41361,832.70-30.91-53.57-36.46-58.9481.74---863.51-1,987.016.43--0.1491---57.97--3.38------
Jbm (Healthcare) Ltd610.30m97.99m725.41m258.008.010.77354.881.190.10870.10870.67861.120.44065.884.102,000,994.007.563.339.044.9347.7045.9717.1710.971.4522.150.121113.8128.1114.51131.906.14-5.09--
JW (Cayman) Therapeutics Co Ltd187.87m-829.88m740.75m398.00--0.4052--3.94-2.02-2.020.45654.410.07041.6865.54472,023.00-31.11-39.77-35.21-44.0050.74---441.74-1,316.813.86-47.820.1592--19.32--9.23---19.87--
Transcenta Holding Limited58.19m-499.84m788.82m215.00--0.7085--13.56-1.23-1.230.1432.550.02812.051.49270,642.30-24.17---33.97--26.74---859.01--1.20-32.870.285---47.15---13.72------
Zhaoke Ophthalmology Ltd20.26m-416.06m856.34m313.00--0.3869--42.27-0.765-0.7650.03734.050.0075--0.343364,731.17-15.43---17.27--75.98---2,053.54--5.32-47.540.1041------5.47------
Hbm Holdings Ltd700.22m178.35m908.76m154.004.730.96584.241.300.24950.24950.96931.220.38863.903.014,546,876.009.88-54.6114.13-66.0497.7397.8125.43-400.283.286.980.3556--120.13127.06116.61------
Brii Biosciences Ltd666.72k-188.92m910.88m128.00--0.2702--1,366.21-0.2597-0.25970.00094.620.0002----5,208.73-5.60---5.84-------29,881.69------0.001---98.80--63.90------
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd909.36m160.15m917.63m848.005.730.57367.481.010.28590.28591.622.860.35872.182.941,072,354.006.327.679.1210.4869.4078.7917.6120.681.51--0.05157.22-0.00495.38-23.43-1.67-1.14--
Zhongzhi Pharmaceutical Holdings Ltd2.21bn175.89m991.86m2.64k5.530.87543.450.44780.20770.20772.621.311.122.5310.54838,056.708.957.6914.1511.7559.7360.568.016.730.894--0.142442.4612.2612.4153.0013.8617.653.22
CStone Pharmaceuticals501.22m-396.83m1.13bn230.00--2.29--2.25-0.3146-0.31460.39680.38440.28112.443.722,179,208.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32--52.42--
Jacobson Pharma Corporation Ltd1.68bn212.16m1.14bn1.59k5.120.47792.880.67740.11120.14090.88221.190.37222.877.50940,829.505.164.916.616.6042.0541.8113.8514.321.015.620.364635.9711.912.8941.304.42-6.226.39
Data as of May 02 2024. Currency figures normalised to Zhaoke Ophthalmology Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

6.69%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 202330.15m5.52%
Janus Henderson Investors US LLCas of 29 Feb 20242.70m0.49%
China Universal Asset Management Co., Ltd.as of 31 Dec 20221.15m0.21%
Janus Henderson Investors UK Ltd.as of 29 Feb 20241.00m0.18%
Amundi (UK) Ltd.as of 29 Feb 2024644.50k0.12%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023525.50k0.10%
SSgA Funds Management, Inc.as of 04 Apr 2024260.88k0.05%
Amundi Hong Kong Ltd.as of 30 Jun 202363.50k0.01%
GF Fund Management Co., Ltd.as of 30 Jun 202347.00k0.01%
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.